ACP-104 or N-Desmethylclozapine (NDMC), or norclozapine is a major metabolite of clozapine, which was developed like a small molecule drug candidate by ACADIA for treatment schizophrenia. ACP-104 combines M1 muscarinic agonist, 5-HT2A inverse agonist, and D2 and D3 dopamine partial agonist in a single compound and, therefore, uniquely addresses what ACADIA believed are the three most promising target mechanisms for treating schizophrenia. Then drug was discontinued, because the study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. The most common adverse events in the treatment arms relative to placebo were increased salivation, tachycardia, and dyspepsia, which were noted to be dose-related. There was no clinically significant decrease in neutrophil counts in the study drug arms.

Tienocarbine is a thienopyridoindole derivative patented by Troponwerke G.m.b.H. und Co. K.-G. as antidepressant. Tienocarbine acts as a mixed dopamine agonist-antagonist

Tidembersat is a benzopyran derivative patented by SmithKline Beecham PLC for treating and preventing a variety of CNS disorders, such as Huntington's chorea, schizophrenia and traumatic brain injury

Tienoxolol is a benzoic acid derivative patented by Centre d'Activite et de Recherche Pharmaceutique Industrielle Biologique et Medicale as β-sympatholytic and diuretic. Tienoxolol acts as a beta-adrenergic receptor antagonist shows potent diuretic and natriuretic activity and, besides that anti-hypertension activity in preclinical models. In clinical trials, Tienoxolol significantly and dose-dependently reduced exercise-induced tachycardia. This effect started 1 h after drug administration, peaked between 4 h and 6 h and lasted at least 12 h.

Zolasartan (previously known as GR 117289) is an angiotensin II (AT1) receptor antagonist that was studied for the treatment of hypertension. It was undergoing phase II clinical trials with Glaxo Wellcome in the United Kingdom before the study was discontinued.

Zoficonazole was developed as an antibacterial and an antifungal agent. Information about the current use of this compound is not available.

Toprilidine is an active peripheral vasodilator and sedative agent. 1 to 1.5 ug given intraarterially augmented the blood flow in the Arteria femoralis of dogs by 100%. Five microg/kg i.v. increased the blood flow in the Arteria femoralis in six dogs on an average by 32%.

Tomoglumide (CR 1392) is the glutaramic acid-derivative. It is a cholecystokinin (CCK) receptor antagonist. The CR 1392 had an inhibitory effect on both CCK-octapeptide (CCK-8)-stimulated immunoreactive insulin (IRI) release and exocrine secretion in the isolated perfused rat pancreas. The concentration of CR 1392 that caused half-maximal inhibition of CCK-8-stimulated IRI release was 300 times lower than that of exocrine secretion. CR 1392 was also effective in reducing the elevated serum amylase activity, pancreatic weight, and histologic alterations even when administered after the pancreatitis had been induced.

Tosulur is a coccidiostat.

Tosagestin (Org 30659) is a synthetic 19-nortestosterone derived progestogen. It was under clinical development by NV Organon for use in oral contraceptive and hormone replacement therapy. After oral administration of [14C]-Org 30659 to postmenopausal women, the compound was extensively metabolized. The dosed radioactivity was predominantly excreted via urine. Org 30659 was to a large extent metabolized at the C3- and the C17-positions. Species comparison of the metabolic routes of Org 30659 after oral administration indicated that the monkey seems to be a better representative species than the rat for the metabolism of Org 30659 in humans. Daily oral administration of Org 30659 suppresses ovarian function to a level sufficient to inhibit ovulation. This effect is dose-dependent, and the suppressive effect is readily reversible at all doses tested. Tosagestin had been in phase II clinical trial for the treatment of the menopausal syndrome. However, this development was discontinued.